ЛИТЕРАТУРА
1. Fraenkel M., Kim M., Faggiano A., de Herder W.W., Valk G.D. Incidence of gastroenteropancreatic neuroendocrine tumours: a systematic review of the literature // Endocr. Relat. Cancer. 2014. Vol. 21, N 3. P. 153-163. DOI: https://doi.org/10.1530/ RC-13-0125
2. Dasari A., Shen C., Halperin D., Zhao B., Zhou S., Xu Y. et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States // JAMA Oncol. 2017. Vol. 3, N 10. P. 1335-1342. DOI: https://doi.org/10.1001/jamaoncol.2017.0589
3. Modlin I.M., Moss S.F., Oberg K., Padbury R., Hicks R.J., Gustafsson B.I., Wright .A. et al. Gastrointestinal neuroendocrine (carcinoid) tumours: current diagnosis and anagement // Med. J. Aust. 2010. Vol. 193, N 1. P. 46-52.
4. Öberg K. The genesis of the neuroendocrine tumors concept: from Oberndorfer to 2018 // Endocrinol. Metab. Clin. North Am. 2018. Vol. 47, N 3. P. 711-731. DOI: https://doi.org/10.1016/j.ecl.2018.05.003
5. Lawrence B., Gustafsson B.I., Chan A., Svejda B., Kidd M., Modlin I.M. The epidemiology of gastroenteropancreatic neuroendocrine tumors // Endocrinol. Metab. Clin. N. Am. 2011. Vol. 40. P. 1-18. DOI: https://doi.org/10.1016/j.ecl.2010.12.005
6. Vinik A.I., Silva M.P., Woltering E.A., Go V.L., Warner R., Caplin M. Biochemical testing for neuroendocrine tumors // Pancreas. 2009. Vol. 38, N 8. P. 876-889. DOI: https://doi.org/10.1097/MPA.0b013e3181bc0e77
7. Jensen R.T., Norton J.A. Treatment of pancreatic neuroendocrine tumors in multiple endocrine neoplasia type 1: some clarity but continued controversy // Pancreas. 2017. Vol. 46, N 5. P. 589-594. DOI: https://doi.org/10.1097/MPA.0000000000000825
8. Ito T., Lee L., Jensen R.T. Treatment of symptomatic neuroendocrine tumor syndromes: recent advances and controversies // Expert Opin. Pharmacother. 2016. Vol. 17, N 16. P. 2191-2205. DOI: https://doi.org/10.1080/14656566.2016.1236916
9. Klimstra D.S. Pathologic Classification of neuroendocrine neoplasms // Hematol. Oncol. Clin. North Am. 2016. Vol. 30, N 1. P. 1-19. OI: https://doi.org/10.1016/j.hoc.2015.08.005
10. Yin X.N., Shen C.Y., Yin Y.Q., Chen H.J., Chen H.N., Yin Y. et al. Prognoses in patients with primary gastrointestinal neuroendocrine neoplasms based on the proposed new classification scheme // Asia Pac. J. Clin. Oncol. 2018. Vol. 14, N 2. P. 37-44. DOI: https://doi.org/10.1111/ajco.12760
11. Pusceddu S., De Braud F., Festinese F., Bregant C., Lorenzoni A., Maccauro M. et al. Evolution in the treatment of gastroenteropancreatic neuroendocrine neoplasms, focus on systemic therapeutic options: a systematic review // Future Oncol. 2015. Vol. 11, N 13. P. 1947-1959. DOI: https://doi.org/10.2217/fon.15.86
12. Laskaratos F.M., Caplin M. Treatment challenges in and outside a network setting: gastrointestinal neuroendocrine tumours // Eur. J. Surg. Oncol. 2019. Vol. 45, N 1. P. 52-59. DOI: https://doi.org/10.1016/j.ejso.2018.03.012
13. Singh S., Granberg D., Wolin E., Warner R., Sissons M., Kolarova T. et al. Patientreported burden of a neuroendocrine tumor (NET) diagnosis: results from the first global survey of patients with NETs // J. Glob. Oncol. 2016. Vol. 3, N 1. P. 43-53. DOI: https://doi.org/10.1200/JGO.2015.002980
14. Chuang C.C., Bhurke S., Chen S.Y., Brulais S., Gabriel S. Clinical characteristics, treatment patterns, and economic burden in patients treated for neuroendocrine tumors in the United States: a retrospective cohort study // J. Med. Econ. 2015. Vol. 18, N 2. P. 126-136. DOI: https://doi.org/10.3111/13696998.2014.975233
15. Lesén E., Granfeldt D., Houchard A., Berthon A., Dinet J., Gabriel S. et al. Cost-ofillness of metastatic gastroenteropancreatic neuroendocrine tumours in Sweden - a population-based register-linkage study // Eur. J. Cancer Care (Engl.). 2019. Vol. 28, N 2. Article ID e12983. DOI: https://doi.org/10.1111/ecc.12983
16. Wolin E.M., Leyden J., Goldstein G., Kolarova T., Hollander R., Warner R.R.P. Patientreported experience of diagnosis, management, and burden of neuroendocrine tumors: results from a large patient survey in the United States // Pancreas. 2017. Vol. 46, N 5. P. 639-647. DOI: https://doi.org/10.1097/MPA.0000000000000818
17. de Herder W.W., Rehfeld J.F., Kidd M., Modlin I.M. A short history of neuroendocrine tumours and their peptide hormones // Best Pract. Res. Clin. Endocrinol. Metab. 2016. Vol. 30, N 1. P. 3-17. DOI: https://doi.org/10.1016/j.beem.2015.10.004
18. Magi L., Mazzuca F., Rinzivillo M., Arrivi G., Pilozzi E., Prosperi D. et al. Multidisciplinary management of neuroendocrine neoplasia: a real-world experience from a referral center // . Clin. Med. 2019. Vol. 8, N 6. Article ID e910. DOI: https://doi.org/10.3390/jcm8060910
19. Pusceddu S., Femia D., Lo Russo G., Ortolani S., Milione M., Maccauro M. et al. Update on medical treatment of small intestinal neuroendocrine tumors // Expert Rev. Anticancer Ther. 2016. Vol. 16, N 9. P. 969-976. DOI: https://doi.org/10.1080/14737140.2016.1207534
20. Begum N., Wellner U., Thorns C., Brabant G., Hoffmann M., Bürk C.G. et al. CUP Syndrome in Neuroendocrine Neoplasia: Analysis of Risk Factors and Impact of Surgical Intervention // World J. Surg. 2015. Vol. 39, N 6. P. 1443-1451. DOI: https://doi.org/10.1007/s00268-015-2963-2
21. Nell S., Verkooijen H.M., Pieterman C.R.C., de Herder W.W., Hermus A.R., Dekkers O.M. et al. Management of MEN1 related nonfunctioning pancreatic NETs: a shifting paradigm: results from the DutchMEN1 Study Group // Ann. Surg. 2018. Vol. 267, N 6. P. 1155-1160. DOI: https://doi.org/10.1097/SLA.0000000000002183
22. Chakedis J., Beal E.W., Lopez-Aguiar A.G., Poultsides G., Makris E., Rocha F.G. et al. Surgery provides long-term survival in patients with metastatic neuroendocrine tumors undergoing resection for non-hormonal symptoms // J. Gastrointest. Surg. 2019. Vol. 23, N 1. P. 122-134. DOI: https://doi.org/10.1007/s11605-018-3986-4
23. Майстренко Н.А., Ромащенко П.Н., Лысанюк М.В. Диагностика и хирургическое лечение нейроэндокринных опухолей поджелудочной железы и желудочно-кишечного тракта // Анналы хирургической гепатологии. 2016. Т. 2, № 1. С. 13-20. DOI: https://doi.org/10.16931/1995-5464.2016113-20
24. Service F.J., Natt N. The prolonged fast // J. Clin. Endocrinol. Metab. 2000. Vol. 85, N 11. P. 3973-3974. DOI: https://doi.org/10.1210/jcem.85.11.6934
25. Zhuge X., Guo C., Chen Y., Feng L., Jia R., Zhao Y. et al. The levels of tumor markers in pancreatic neuroendocrine carcinoma and their values in differentiation between pancreatic neuroendocrine carcinoma and pancreatic ductal adenocarcinoma // Pancreas. 2018. Vol. 47, N 10. P. 1290-1295. DOI: https://doi.org/10.1097/MPA.0000000000001181
26. Partelli S., Maurizi A., Tamburrino D., Baldoni A., Polenta V., Crippa S. et al. GEP-NETS update: a review on surgery of gastro-entero-pancreatic neuroendocrine tumors // Eur. J. Endocrinol. 2014. Vol. 171, N 4. P. 153-162. OI: https://doi.org/10.1530/EJE-14-0173
27. Tochetto S., Yaghmai V. CT enterography: concept, technique, and interpretation // adiol. Clin. North Am. 2009. Vol. 47, N 1. P. 117-132. DOI: https://doi.org/10.1016/j. cl.2008.10.007 28. Tamm E.P., Bhosale P., Lee J.H., Rohren E.M. State-of-the-art imaging of pancreatic neuroendocrine tumors // Surg. Oncol. Clin. N. Am. 2016. Vol. 25, N 2. P. 375-400. DOI: https://doi.org/10.1016/j.soc.2015.11.007
29. Scialpi M., Reginelli A., D’Andrea A., Gravante S., Falcone G., Baccari P. et al. Pancreatic tumors imaging: an update // Int. J. Surg. 2016. Vol. 28, suppl. 1. P. 142-155. DOI: https:// doi.org/10.1016/j.ijsu.2015.12.053
30. Ronot M., Clift A.K., Vilgrain V., Frilling A. Functional imaging in liver tumours // J. Hepatol. 2016. Vol. 65, N 5. P. 1017-1030. OI: https://doi.org/10.1016/j.jhep.2016.06.024
31. Deroose C.M., Hindié E., Kebebew E., Goichot B., Pacak K., Taïeb D. et al. Molecular imaging of gastroenteropancreatic neuroendocrine tumors: current status and future directions // J. Nucl. Med. 2016. Vol. 57, N 12. P. 1949-1956. OI: https://doi.org/10.2967/ jnumed.116.179234
32. Polkowski M., Larghi A., Weynand B., Boustière C., Giovannini M., Pujol B. et l. Learning, techniques, and complications of endoscopic ultrasound (EUS)-guided ampling in gastroenterology: European Society of Gastrointestinal Endoscopy (ESGE) echnical Guideline // Endoscopy. 2012. Vol. 44, N 2. P. 190-206. DOI: https://doi. rg/10.1055/s-0031-1291543
33. Ramage J.K., De Herder W.W., Delle Fave G., Ferolla P., Ferone D., Ito T. et al. NETS Consensus Guidelines update for colorectal neuroendocrine neoplasms // Neuroendocrinology. 2016. Vol. 103, N 2. P. 139-143. DOI: https://doi.org/10.1159/000443166
34. Doppman J.L., Miller D.L., Chang R., Gorden P., Eastman R.C., Norton J.A. Intraarterial calcium stimulation test for detection of insulinomas // World J. Surg. 1993. Vol. 17, N 4. P. 439-443.
35. Thompson S.M., Vella A., Thompson G.B., Rumilla K.M., Service F.J., Grant C.S. t al. Selective arterial calcium stimulation with hepatic venous sampling differentiates nsulinoma from nesidioblastosis // J. Clin. Endocrinol. Metab. 2015. Vol. 100, N 11. . 4189-4197. DOI: https://doi.org/10.1210/jc.2015-2404
36. Ohrvall U., Eriksson B., Juhlin C., Karacagil S., Rastad J., Hellman P. et al. Method for dissection of mesenteric metastases in mid-gut carcinoid tumors // World J. Surg. 2000. Vol. 24, N 11. P. 1402-1408.
37. Mocellin S., Nitti D. Gastrointestinal carcinoid: epidemiological and survival evidence from a large population-based study (n = 25 531) // Ann. Oncol. 2013. Vol. 24, N 12. P. 3040-3044. DOI: https://doi.org/10.1093/annonc/mdt377
38. Kasumova G.G., Tabatabaie O., Eskander M.F., Tadikonda A., Ng S.C., Tseng J.F. National rise of primary pancreatic carcinoid tumors: comparison to functional and nonfunctional pancreatic neuroendocrine tumors // J. Am. Coll. Surg. 2017. Vol. 224, N 6. P. 1057-1064. DOI: https://doi.org/10.1016/j.jamcollsurg.2016.11.014
39. Siegel R.L., Miller K.D., Jemal A. Cancer statistics, 2018 // CA Cancer J. Clin. 2018. Vol. 68, N 1. P. 7-30. DOI: https://doi.org/10.3322/caac.21442
40. Modlin I.M., Oberg K., Taylor A., Drozdov I., Bodei L., Kidd M. Neuroendocrine tumor biomarkers: current status and perspectives // Neuroendocrinology. - 2014. - Vol. 100, N 4. - P. 265-277. DOI: https://doi.org/10.1159/000368363.
41. Marotta V., Zatelli M.C., Sciammarella C., Ambrosio M.R., Bondanelli M., Colao A. et al. Chromogranin A as circulating marker for diagnosis and management of neuroendocrine neoplasms: more flaws than fame // Endocr. Relat. Cancer. 2018. Vol. 25, N 1. P. 11-29. DOI: https://doi.org/10.1530/ERC-17-0269
42. Oberg K., Modlin I.M., De Herder W., Pavel M., Klimstra D., Frilling A. et al. Consensus on biomarkers for neuroendocrine tumour disease // Lancet Oncol. 2015. Vol. 16, N 9. P. 435-446. DOI: https://doi.org/10.1016/S1470-2045(15)00186-2
43. Zandee W.T., Kamp K., van Adrichem R.C., Feelders R.A., de Herder W.W. Limited value for urinary 5-HIAA excretion as prognostic marker in gastrointestinal neuroendocrine tumours // Eur. J. Endocrinol. 2016. Vol. 175, N 5. P. 361-366. DOI: https://doi. org/10.1530/EJE-16-0392
44. Mehrabi A., Fischer L., Hafezi M., Dirlewanger A., Grenacher L., Diener M.K. et al. A systematic review of localization, surgical treatment options, and outcome of insulinoma // Pancreas. 2014. Vol. 43, N 5. P. 675-686. DOI: https://doi.org/10.1097/MPA.0000000000000110
45. Berna M.J., Hoffmann K.M., Serrano J., Gibril F., Jensen R.T. Serum gastrin in Zollinger-Ellison syndrome: I. Prospective study of fasting serum gastrin in 309 patients from the National Institutes of Health and comparison with 2229 cases from the literature // Medicine (Baltimore). 2006. Vol. 85, N 6. P. 295-330. DOI: https://doi.org/10.1097/01.md.0000236956.74128.76
46. Ito T., Cadiot G., Jensen R.T. Diagnosis of Zollinger-Ellison syndrome: increasingly difficult // World J. Gastroenterol. 2012. Vol. 18, N 39. P. 5495-5503. DOI: https://doi. org/10.3748/wjg.v18.i39.5495
47. Norton J.A., Foster D.S., Ito T., Jensen R.T. Gastrinomas: medical or surgical treatment // Endocrinol. Metab. Clin. North Am. 2018. Vol. 47, N 3. P. 577-601. DOI: https://doi. org/10.1016/j.ecl.2018.04.009
48. Bodei L., Sundin A., Kidd M., Prasad V., Modlin I.M. The status of neuroendocrine tumor imaging: from darkness to light? // Neuroendocrinology. 2015. Vol. 101, N 1. P. 1-17. DOI: https://doi.org/10.1159/000367850
49. Ромащенко П.Н., Майстренко Н.А., Орлова Р.В., Лысанюк М.В. Обоснование лечебно-диагностической тактики у больных нейроэндокринными опухолями тонкой кишки // Вестник хирургии им. И.И. Грекова. 2018. T. 177, № 4. C. 28-37.
50. Öberg K., Sundin A. Imaging of neuroendocrine tumors // Front. Horm. Res. 2016. Vol. 45. P. 142-151. DOI: https://doi.org/10.1159/000442331
51. Lee L., Ito T., Jensen R.T. Imaging of pancreatic neuroendocrine tumors: recent advances, current status, and controversies // Expert Rev. Anticancer Ther. 2018. Vol. 18, N 9. P. 837-860. DOI: https://doi.org/10.1080/14737140.2018.1496822
52. Lewis R.B., Lattin G.E. Jr, Paal E. Pancreatic endocrine tumors: radiologicclinicopathologic correlation // Radiographics. 2010. Vol. 30, N 6. P. 1445-1464. DOI: https://doi.org/10.1148/rg.306105523
53. Cappelli C., Boggi U., Mazzeo S., Cervelli R., Campani D., Funel N. et al. Contrast enhancement pattern on multidetector CT predicts malignancy in pancreatic endocrine tumours // Eur. Radiol. 2015. Vol. 25, N 3. P. 751-759. OI: https://doi.org/10.1007/s00330-014-3485-2
54. Belousova E., Karmazanovsky G., Kriger A., Kalinin D., Mannelli L., Glotov A. et l. Contrast-enhanced MDCT in patients with pancreatic neuroendocrine tumours: correlation with histological findings and diagnostic performance in differentiation between tumour grades // Clin. Radiol. 2017. Vol. 72, N 2. P. 150-158. DOI: https://doi.org/10.1016/j.crad.2016.10.021
55. Kim J.H., Eun H.W., Kim Y.J., Lee J.M., Han J.K., Choi B.I. Pancreatic neuroendocrine tumour (PNET): Staging accuracy of MDCT and its diagnostic performance for the differentiation of PNET with uncommon CT findings from pancreatic adenocarcinoma // Eur. Radiol. 2016. Vol. 26, N 5. P. 1338-1347. DOI: https://doi.org/10.1007/s00330-015-3941-7
56. Fletcher J.G., Wiersema M.J., Farrell M.A., Fidler J.L., Burgart L.J., Koyama T. et al. Pancreatic malignancy: value of arterial, pancreatic, and hepatic phase imaging with multi-detector row CT // Radiology. 2003. Vol. 229, N 1. P. 81-90. DOI: https://doi.org/10.1148/radiol.2291020582
57. Gandhi N.S., Feldman M.K., Le O., Morris-Stiff G. Imaging mimics of pancreatic ductal adenocarcinoma // Abdom. Radiol (N. Y.). 2018. Vol. 43, N 2. P. 273-284. DOI: https:// doi.org/10.1007/s00261-017-1330-1
58. Ito T., Jensen R.T. Molecular imaging in neuroendocrine tumors: recent advances, controversies, unresolved issues, and roles in management // Curr. Opin. Endocrinol. Diabetes Obes. 2017. Vol. 24, N 1. P. 15-24. OI: https://doi.org/10.1097/MED.0000000000000300
59. Yang Z., Klimstra D.S., Hruban R.H., Tang L.H. Immunohistochemical characterization of the origins of metastatic well-differentiated neuroendocrine tumors to the liver // Am. J. Surg. Pathol. 2017. Vol. 41, N 7. P. 915-922. DOI: https://doi.org/10.1097/PAS.0000000000000876
60. Maxwell J.E., Sherman S.K., Stashek K.M., O’Dorisio T.M., Bellizzi A.M., Howe J.R. A practical method to determine the site of unknown primary in metastatic neuroendocrine tumors // Surgery. 2014. Vol. 156, N 6. P. 1359-1365. DOI: https://doi.org/10.1016/j.surg.2014.08.008
61. Kyriakopoulos G., Mavroeidi V., Chatzellis E., Kaltsas G.A., Alexandraki K.I. Histopathological, immunohistochemical, genetic and molecular markers of neuroendocrine neoplasms // Ann. Transl. Med. 2018. Vol. 6, N 12. P. 252. DOI: https:// oi.org/10.21037/atm.2018.06.27
62. Eriksson J., Garmo J.E.H., Ihre-Lundgren C., Hellman P. Prognostic factors for death after surgery for small intestinal neuroendocrine tumours // BJS Open. 2018. Vol. 2, N 5. . 345-352. DOI: https://doi.org/10.1002/bjs5.76. 63. Smith J.K., Ng S.C., Hill J.S., Simons J.P., Arous E.J., Shah S.A. et al. Complications after pancreatectomy for neuroendocrine tumors: a national study // J. Surg. Res. 2010. Vol. 163, N 1. P. 63-68. DOI: https://doi.org/10.1016/j.jss.2010.04.017
64. Jilesen A.P., van Eijck C.H., in’t Hof K.H., van Dieren S., Gouma D.J., van Dijkum E.J. Postoperative complications, in-hospital mortality and 5-year survival after surgical resection for patients with a pancreatic neuroendocrine tumor: a systematic review // World J. Surg. 2016. Vol. 40, N 3. P. 729-748. DOI: https://doi.org/10.1007/s00268-015-3328-6
65. Лысанюк М.В., Ромащенко П.Н., Орлова Р.В. Выбор тактики лечения больных нейроэндокринными опухолями // Таврический медико-биологический вестник. 2018. T. 21, № 1. C. 84-97.
66. Maxwell J.E., Sherman S.K., O’Dorisio T.M., Bellizzi A.M., Howe J.R. Liver-directed surgery of neuroendocrine metastases: what is the optimal strategy? // Surgery. 2016. Vol. 159, N 1. P. 320-333. DOI: https://doi.org/10.1016/j.surg.2015.05.040
67. Morgan R.E., Pommier S.J., Pommier R.F. Expanded criteria for debulking of liver metastasis also apply to pancreatic neuroendocrine tumors // Surgery. 2018. Vol. 163, N 1. P. 218-225. DOI: https://doi.org/10.1016/j.surg.2017.05.030
68. Ejaz A., Reames B.N., Maithel S., Poultsides G.A., Bauer T.W., Fields R.C. et al. The impact of extrahepatic disease among patients undergoing liver-directed therapy for neuroendocrine liver metastasis // J. Surg. Oncol. 2017. Vol. 116, N 7. P. 841-847. DOI: https://doi.org/10.1002/jso.24727
69. Daskalakis K., Karakatsanis A., Hessman O., Stuart H.C., Welin S., Tiensuu Janson E. et al. Association of a prophylactic surgical approach to stage IV small intestinal neuroendocrine tumors with survival // JAMA Oncol. 2018. Vol. 4, N 2. P. 183-189. DOI: https://doi.org/10.1001/jamaoncol.2017.3326
70. Zhou B., Zhan C., Ding Y., Yan S., Zheng S. Role of palliative resection of the primary pancreatic neuroendocrine tumor in patients with unresectable metastatic liver disease: a systematic review and meta-analysis // Onco Targets Ther. 2018. Vol. 11. P. 975-982. DOI: https://doi.org/10.2147/OTT.S158171
71. Citterio D., Pusceddu S., Facciorusso A., Coppa J., Milione M., Buzzoni R. et al. Primary tumour resection may improve survival in functional well-differentiated neuroendocrine tumours metastatic to the liver // Eur. J. Surg. Oncol. 2017. Vol. 43, N 2. P. 380-387. DOI: https://doi.org/10.1016/j.ejso.2016.10.031
72. Kaçmaz E., Heidsma C.M., Besselink M.G.H., Dreijerink K.M.A., Klümpen H.J., Nieveen van Dijkum E.J.M. et al. Treatment of liver metastases from midgut neuroendocrine tumours: a systematic review and meta-analysis // J. Clin. Med. 2019. Vol. 8, N 3. P. 403. DOI: https://doi.org/10.3390/jcm8030403
73. Gupta S. Intra-arterial liver-directed therapies for neuroendocrine hepatic metastases // Semin. Intervent. Radiol. 2013. Vol. 30, N 1. P. 28-38. OI: https://doi.org/10.1055/s-0033-1333651
74. Cavalcoli F., Rausa E., Conte D., Nicolini A.F., Massironi S. Is there still a role for the hepatic locoregional treatment of metastatic neuroendocrine tumors in the era of systemic targeted therapies? // World J. Gastroenterol. 2017. Vol. 23, N 15. P. 2640-2650. DOI:https://doi.org/10.3748/wjg.v23.i15.2640
75. Kennedy A.S. Hepatic-directed therapies in patients with neuroendocrine tumors // Hematol. Oncol. Clin. North Am. 2016. Vol. 30, N 1. P. 193-207. DOI: https://doi.org/10.1016/j.hoc.2015.09.010
76. Pavel M., O’Toole D., Costa F., Capdevila J., Gross D., Kianmanesh R. et al. ENETS Consensus Guidelines update for the management of distant metastatic disease of intestinal, pancreatic, bronchial neuroendocrine neoplasms (NEN) and NEN of unknown primary site // Neuroendocrinology. 2016. Vol. 103, N 2. P. 172-185. DOI: https://doi.org/10.1159/000443167
77. Singh S., Asa S.L., Dey C., Kennecke H., Laidley D., Law C. et al. Diagnosis and management of gastrointestinal neuroendocrine tumors: an evidence-based Canadian consensus // Cancer Treat. Rev. 2016. Vol. 47. P. 32-45. DOI: https://doi.org/10.1016/j.ctrv.2016.05.003
78. Kolbeck K.J., Farsad K. Catheter-based treatments for hepatic metastases from neuroendocrine tumors // AJR Am. J. Roentgenol. 2014. Vol. 203, N 4. Р. 717-724. DOI: https://doi.org/10.2214/AJR.14.12983
79. Shamimi-Noori S., Gonsalves C.F., Shaw C.M. Metastatic liver disease: indications for locoregional therapy and supporting data // Semin. Intervent. Radiol. 2017. Vol. 34, N 2. Р. 145-166. DOI: https://doi.org/10.1055/s-0037-1602712
80. Майстренко Н.А., Ромащенко П.Н., Орлова Р.В., Лысанюк М.В. Возможности ечения больных с генерализованными нейроэндокринными опухолями // Онкология. Журнал им. П.А. Герцена. 2018. Т. 7, № 2. С. 16-25. DOI: https://doi.org/10.17116/onkolog20187216-25
81. Garcia-Carbonero R., Sorbye H., Baudin E., Raymond E., Wiedenmann B., Niederle B. et al. ENETS Consensus Guidelines for high-grade gastroenteropancreatic neuroendocrine tumors and neuroendocrine carcinomas // Neuroendocrinology. 2016. Vol. 103, N 2. P. 186-194. DOI: https://doi.org/10.1159/000443172
82. Haugvik S.P., Janson E.T., Österlund P., Langer S.W., Falk R.S., Labori K.J. et al. Surgical Treatment as a principle for patients with high-grade pancreatic neuroendocrine carcinoma: a nordic multicenter comparative study // Ann. Surg. Oncol. 2016. Vol. 23, N 5. P. 1721-1728. DOI: https://doi.org/10.1245/s10434-015-5013-2
83. Du S., Ni J., Weng L., Ma F., Li S., Wang W. et al. aggressive locoregional treatment improves the outcome of liver metastases from grade 3 gastroenteropancreatic neuroendocrine tumors // Medicine (Baltimore). 2015. Vol. 94, N 34. P. 1429. DOI: https://doi.org/10.1097/ MD.0000000000001429
84. Galleberg R.B., Knigge U., Tiensuu Janson E., Vestermark L.W., Haugvik S.P., Ladekarl M. et al. Results after surgical treatment of liver metastases in patients with high-grade gastroenteropancreatic neuroendocrine carcinomas // Eur. J. Surg. Oncol. 2017. Vol. 43, N 9. P. 1682-1689. DOI: https://doi.org/10.1016/j.ejso.2017.04.010
85. Bilimoria K.Y., Bentrem D.J., Wayne J.D., Ko C.Y., Bennett C.L., Talamonti M.S. Small bowel cancer in the United States: changes in epidemiology, treatment, and survival over the last 20 years // Ann. Surg. 2009. Vol. 249, N 1. P. 63-71. DOI: https://doi.org/10.1097/SLA.0b013e31818e4641
86. Pokrzywa C.J., Abbott D.E., Matkowskyj K.A., Ronnekleiv-Kelly S.M., Winslow E.R., Weber S.M. et al. Natural history and treatment trends in pancreatic cancer subtypes // J. Gastrointest. Surg. 2019. Vol. 23, N 4. P. 768-778. DOI: https://doi.org/10.1007/s11605-019-04113-3
87. Dieckhoff P., Runkel H., Daniel H., Wiese D., Koenig A., Fendrich V. et al. Welldifferentiated neuroendocrine neoplasia: relapse-free survival and predictors of recurrence after curative intended resections // Digestion. 2014. Vol. 90, N 2. P. 89-97. DOI: https://doi.org/10.1159/000365143
88. Merath K., Bagante F., Beal E.W., Lopez-Aguiar A.G., Poultsides G., Makris E. et al. Nomogram predicting the risk of recurrence after curative-intent resection of primary non-metastatic gastrointestinal neuroendocrine tumors: an analysis of the U.S. Neuroendocrine Tumor Study Group // J. Surg. Oncol. 2018. Vol. 117, N 5. P. 868-878. OI: https://doi.org/10.1002/jso.24985
89. Martin-Perez E., Capdevila J., Castellano D., Jimenez-Fonseca P., Salazar R., Beguiristain-Gomez A. et al. Prognostic factors and long-term outcome of pancreatic neuroendocrine neoplasms: Ki-67 index shows a greater impact on survival than disease stage. The large experience of the Spanish National Tumor Registry (RGETNE) // Neuroendocrinology. 2013. Vol. 98, N 2. P. 156-168. DOI: https://doi.org/10.1159/000355152
90. Yao J.C., Hassan M., Phan A., Dagohoy C., Leary C., Mares J.E., Adalla E.K. et al. One hundred years after "carcinoid": Epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States // J. Clin. Oncol. 2008. Vol. 26, N 18. P. 3063-3072. DOI: https://doi.org/10.1200/JCO.2007.15.4377
91. Niederle M.B., Niederle B.N. Diagnosis and treatment of gastroenteropancreatic neuroendocrine tumors: current data on a prospectively collected, retrospectively analyzed clinical multicenter investigation // Oncologist. 2011. Vol. 16. P. 602-613. DOI: https://doi.org/10.1634/theoncologist.2011-0002
92. Shanahan M.A., Salem A., Fisher A., Cho C.S., Leverson G., Winslow E.R. et al. Chromogranin A predicts survival for resected pancreatic neuroendocrine tumors // J.Surg. Res. 2016. Vol. 201, N 1. P. 38-43. OI: https://doi.org/10.1016/j.jss.2015.10.006
93. Ruzzenente A., Bagante F., Bertuzzo F., Aldrighetti L., Ercolani G., Giuliante F. et al. A Novel nomogram to predict the prognosis of patients undergoing liver resection for neuroendocrine liver metastasis: an analysis of the Italian neuroendocrine liver metastasis database // J. Gastrointest. Surg. 2017. Vol. 21, N 1. P. 41-48. DOI: https://doi.org/10.1007/s11605-016-3228-6
94. Pusceddu S., Barretta F., Trama A., Botta L., Milione M., Buzzoni R. et al. A classification prognostic score to predict OS in stage IV well-differentiated neuroendocrine tumor // Endocr. Relat. Cancer. 2018. Vol. 25, N 6. P. 607-618. DOI: https://doi.org/10.1530/ERC-17-0489
95. Batukbhai B.D.O., De Jesus-Acosta A. The molecular and clinical landscape of pancreatic neuroendocrine tumors // Pancreas. 2019. Vol. 48, N 1. P. 9-21. DOI: https://doi.org/10.1097/MPA.0000000000001189
96. Bösch F., Brüwer K., Altendorf-Hofmann A., Auernhammer C.J., Spitzweg C., Westphalen C.B. et al. Immune checkpoint markers in gastroenteropancreatic neuroendocrine neoplasia // Endocr. Relat. Cancer. 2019. Vol. 26, N 3. P. 293-301. DOI: https://doi.org/10.1530/ERC-18-0494
97. Norlen O., Stalberg P., Oberg K., Eriksson J., Hedberg J., Hessman O. et al. Long-term results of surgery for small intestinal neuroendocrine tumors at a tertiary referral center // World J. Surg. 2012. Vol. 36. P. 1419-1431. DOI: https://doi.org/10.1007/s00268-011-1296-z
98. Lee L., Igarashi H., Fujimori N., Hijioka M. Long-term outcomes and prognostic factors in 78 Japanese patients with advanced pancreatic neuroendocrine neoplasms: a singlecenter retrospective study // Jpn. J. Clin. Oncol. 2015. Vol. 45, N 12. P. 1131-1138. DOI: https://doi.org/10.1093/jjco/hyv143.